FY2024 Earnings Estimate for Windtree Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:WINT)

Windtree Therapeutics, Inc. (NASDAQ:WINT) – Equities researchers at HC Wainwright increased their FY2024 earnings estimates for shares of Windtree Therapeutics in a research note issued on Tuesday, July 9th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($2.38) per share for the year, up from their prior forecast of ($17.31). The consensus estimate for Windtree Therapeutics’ current full-year earnings is ($17.47) per share. HC Wainwright also issued estimates for Windtree Therapeutics’ FY2025 earnings at ($2.13) EPS.

Windtree Therapeutics (NASDAQ:WINT) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($9.25) earnings per share (EPS) for the quarter.

Windtree Therapeutics Stock Performance

NASDAQ WINT opened at $3.82 on Thursday. The firm’s 50 day moving average price is $3.63 and its 200-day moving average price is $6.19. Windtree Therapeutics has a 52-week low of $2.89 and a 52-week high of $30.06. The company has a market cap of $2.25 million, a PE ratio of -0.11 and a beta of 0.56.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.